<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35032">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755520</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. D00112</org_study_id>
    <secondary_id>2012-003630-16</secondary_id>
    <nct_id>NCT01755520</nct_id>
  </id_info>
  <brief_title>Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG</brief_title>
  <acronym>TiCAB</acronym>
  <official_title>A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study (TiCAB) is designed as a pivotal efficacy and safety study of Ticagrelor in
      patients undergoing coronary artery bypass operation. It is designed for the prevention of
      fatal and non-fatal cardiovascular events in this patient population, a significant, yet
      unmet medical need.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For stable patients who underwent coronary bypass operation, Aspirin alone currently
      represents the gold standard of antiplatelet treatment. A few smaller studies using a
      combination therapy of antiplatelet drugs including Aspirin and Clopidogrel have shown
      conflicting results. Albeit a number of cardiac surgeons prefer dual antiplatelet therapy
      with Aspirin and Clopidogrel, Aspirin monotherapy is currently the only guideline
      recommended therapy after CABG.

      A sub-analysis of PLATO trial comprising more than 1200 ACS patients who were not considered
      to be appropriately suited for PCI and therefore subjected to CABG operation demonstrated an
      impressive reduction in mortality in those patients treated with Ticagrelor and Aspirin as
      compared to Clopidogrel and Aspirin. The labelling of Ticagrelor says that the drug should
      be paused 7 days prior to surgery. However, a further analysis of this substudy revealed
      that the largest benefit in the Ticagrelor + Aspirin group as compared to the Clopidogrel +
      Aspirin group was found in those who stopped study medication at about 48 - 72 hours prior
      to surgery. There have been pharmacological studies that showed that Ticagrelor may
      precondition the heart for the trauma of surgery via adenosine mediated effects. Thus, the
      enormous benefit in the Ticagrelor arm of the PLATO study may be secondary to a pleiotropic
      action. There was no indication of an accelerated bleeding risk in this study and
      pharmacological studies document that platelet function should be largely restored of a
      pause of 48 - 72 hours, such that this duration may allow the optimal preparation for CABG
      surgery.

      Based on the unmet clinical need regarding optimal antiplatelet therapy after CABG, the
      results of the PLATO CABG substudy and the observation that Ticagrelor benefits increase
      with decreasing Aspirin doses, Ticagrelormonotherapy (2x 90mg/day) appears to offer the best
      balance of safety with anticipated improved efficacy over Aspirin alone. However, there are
      no data available to support this hypothesis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>MACCE</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Composite of cardiovascular death, myocardial infarction, target vessel revascularization, and stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding events</measure>
    <time_frame>within 12 months after coronary arerty bypass surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of major bleeding events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>All cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4008</enrollment>
  <condition>Coronary Artery Desease,</condition>
  <condition>Stable Angina,</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: Ticagrelor verum + Aspirin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: Aspirin verum + Ticagrelor placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>90mg twice daily dose</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 100mg once daily</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>ASS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Ticagrelor</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Aspirin</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years of age or older

          2. Informed, written consent by the patient

          3. Indication for CABG surgery:

               -  coronary three vessel disease, or

               -  left main stenosis, or

               -  two vessel disease with impaired left ventricular function

        Exclusion Criteria:

          1. Indication for oral anticoagulation therapy (i.e. AF) at the time of randomization

          2. Cardiogenic shock, haemodynamic instability

          3. Acute myocardial infarction at presentation (STEMI)

          4. Need for urgent revascularization within 5 days from presentation

          5. Single or two vessel disease with normal LV function (≥ 50%)

          6. Need for concomitant non-coronary surgery (e.g. valve replacement)

          7. Contraindication for Aspirin or Ticagrelor use (i.e. known allergy)

          8. History of bleeding diathesis within three months prior presentation, significant GI
             bleed, intra cranial hemorrhage, or liver failure

          9. Patient requires dialysis

         10. Known, clinically important thrombocytopenia (i.e. &lt;100.000/µl)

         11. Known, clinically important anaemia (i.e. &lt;10mg/dl)

         12. Participation in another investigational drug or device study in the last 30 days

         13. Pregnancy or lactation (for premenopausal women 2 methods of reliable contraception,
             one of which must be barrier method, are required)

         14. Concomitant oral or intravenous therapy (see examples below) with strong CYP3A
             inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A
             inducers which cannot be stopped for the course of the study

               -  Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin,
                  clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir,
                  atanazavir, over 1 litre daily of grapefruit juice.

               -  Substrates with narrow therapeutic index: cyclosporine, quinidine.

               -  Strong inducers: rifampin/rifampicin, phenytoin, carbamazepine.

         15. Any other condition such as active cancer

         16. Life expectancy less than 12 months that may result in protocol non-compliance or a
             risk for being lost to follow-up

         17. Indication for major surgery (e.g. cancer treatment, carotid surgery, cerebral
             surgery, major vascular surgery)

         18. Previous enrolment or randomization of treatment in the present study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heribert Schunkert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Munich Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heribert Schunkert, MD</last_name>
    <phone>00498912184073</phone>
    <email>schunkert@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gisela Schoemig</last_name>
    <phone>00498912181547</phone>
    <email>gschoemig@dhm.mhn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrid Sandner, MD</last_name>
      <phone>+43-140400</phone>
      <phone_ext>6969</phone_ext>
      <email>sigrid.sandner@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Sigird Sandner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heribert Schunkert, MD</last_name>
      <phone>00498912184073</phone>
      <email>schunkert@dhm.mhn.de</email>
    </contact>
    <contact_backup>
      <last_name>Adnan Kastrati, MD</last_name>
      <phone>00498912184578</phone>
      <email>kastrati@dhm.mhn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Heribert Schunkert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rüdiger Autschbach, MD</last_name>
      <phone>+49-241-80</phone>
      <phone_ext>89221</phone_ext>
      <email>rautschbach@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Rüdiger Autschbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gesundheit Nord gGmbH, Klinikum Links der Weser gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Hambrecht, MD</last_name>
      <phone>+49-421-879</phone>
      <phone_ext>1430</phone_ext>
      <email>rainer.hambrecht@klinikum-bremen-LdW.de</email>
    </contact>
    <investigator>
      <last_name>Rainer Hambrecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sana Herzzentrum Cottbus GmbH</name>
      <address>
        <city>Cottbus</city>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jürgen Krülls-München, MD</last_name>
      <phone>+49-355-46</phone>
      <phone_ext>2576</phone_ext>
      <email>1.med.klinik@ctk.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Krülls-Münch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Malte Kelm, MD</last_name>
      <phone>+49-211-811</phone>
      <phone_ext>8801</phone_ext>
      <email>malte.kelm@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Malte Kelm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Schlundt, MD</last_name>
      <phone>+49-9131-853</phone>
      <phone_ext>5000</phone_ext>
      <email>christian.schlundt@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Christian Schlundt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg / Bad Krozingen</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Siepe, MD</last_name>
      <phone>+49-761-2702</phone>
      <phone_ext>4010</phone_ext>
      <email>matthias.siepe@universitaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Siepe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Böning, MD</last_name>
      <phone>+49-641-985</phone>
      <phone_ext>44300</phone_ext>
      <email>andreas.boening@chiru.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Böning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Danner, MD</last_name>
      <phone>+49-551-39</phone>
      <phone_ext>6061</phone_ext>
      <email>bernd.danner@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Bernd Danner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Attmann, MD</last_name>
      <phone>+49-431-597</phone>
      <phone_ext>4465</phone_ext>
      <email>tim.attmann@uksh-kiel.de</email>
    </contact>
    <investigator>
      <last_name>Tim Attmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Misfeld, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martin Misfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Zeymer, MD</last_name>
      <phone>+49-621-503</phone>
      <phone_ext>2941</phone_ext>
      <email>zeymeru@klilu.de</email>
    </contact>
    <investigator>
      <last_name>Uwe Zeymer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Reppel, MD</last_name>
      <phone>+49-451-500</phone>
      <phone_ext>2500</phone_ext>
      <email>michael.reppel@uk-sh.de</email>
    </contact>
    <investigator>
      <last_name>Michael Reppel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivar Friedrich, MD</last_name>
      <phone>+49-651-208</phone>
      <phone_ext>2751</phone_ext>
      <email>i.friedrich@bk-trier.de</email>
    </contact>
    <investigator>
      <last_name>Ivar Friedrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>December 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CABG,</keyword>
  <keyword>CAD,</keyword>
  <keyword>antiplatelet drug,</keyword>
  <keyword>Ticagrelor,</keyword>
  <keyword>Aspirin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
